CADLCandel Therapeutics, Inc.

CADL Stock Price, Valuation & Chart | Candel Therapeutics, Inc.

Compare

$13.200+0.35 (+2.72%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology CADL intrinsic value CADL calculated fair value vs price

Overview Financials Dividends Ratios

CADL Historical price chart

CADL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization967.17M

PE Ratio-9.36

EPS-1.41

Trading Volume805.58K

Today's High/Low13.41/12.67

Dividend Yield0.00

52 Week High/Low14.0/4.35

Shares Outstanding73.27M

CADL Financial Statement

CADL Analyst ratings

CADL Analysis & performance metrics

CADL Company profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409,…

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has…

CADL Management team

Name

Position

Susan Stewart J.D., L.L.M.

Chief Regulatory Officer

Ileen B. Winick

Chief People Officer

Paul-Peter Tak FOCIS, M.D., Ph.D.CEO

President, Chief Executive Officer & Director

William Garrett Nichols M.D., M.S.

Chief Medical Officer

Seshu Tyagarajan Ph.D.

Chief Technical & Development Officer

Francesca Barone M.D., Ph.D.

Chief Scientific Officer

Charles SchochCFO

Interim Chief Financial Officer, Principal Accounting Officer, Treasurer & Secretary

Name

Position

Susan Stewart J.D., L.L.M.

Chief Regulatory Officer

Ileen B. Winick

Chief People Officer

Paul-Peter Tak FOCIS, M.D., Ph.D.CEO

President, Chief Executive Officer & Director

William Garrett Nichols M.D., M.S.

Chief Medical Officer

Seshu Tyagarajan Ph.D.

Chief Technical & Development Officer

Francesca Barone M.D., Ph.D.

Chief Scientific Officer

Charles SchochCFO

Interim Chief Financial Officer, Principal Accounting Officer, Treasurer & Secretary

Management Team

Susan Stewart J.D., L.L.M.

Chief Regulatory Officer

Ileen B. Winick

Chief People Officer

Paul-Peter Tak FOCIS, M.D., Ph.D.CEO

President, Chief Executive Officer & Director

William Garrett Nichols M.D., M.S.

Chief Medical Officer

Seshu Tyagarajan Ph.D.

Chief Technical & Development Officer

Francesca Barone M.D., Ph.D.

Chief Scientific Officer

Charles SchochCFO

Interim Chief Financial Officer, Principal Accounting Officer, Treasurer & Secretary

Management

Susan Stewart J.D., L.L.M.

Chief Regulatory Officer

Ileen B. Winick

Chief People Officer

Paul-Peter Tak FOCIS, M.D., Ph.D.CEO

President, Chief Executive Officer & Director

William Garrett Nichols M.D., M.S.

Chief Medical Officer

Seshu Tyagarajan Ph.D.

Chief Technical & Development Officer

Francesca Barone M.D., Ph.D.

Chief Scientific Officer

Charles SchochCFO

Interim Chief Financial Officer, Principal Accounting Officer, Treasurer & Secretary

Total 7 executives

CADL Frequently asked questions

What is Candel Therapeutics, Inc. (CADL) Stock Price?

Current stock price of Candel Therapeutics, Inc. (CADL) stock is $13.200. The stock price is +2.72% higher in the session. The intraday range can be seen from this page. Volume of Candel Therapeutics, Inc. (CADL) stock is 805.58K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Candel Therapeutics, Inc. (CADL) stock price going up or down today?

The stock price of Candel Therapeutics, Inc. (CADL) can change with earnings, company news, and overall market sentiment. Candel Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Candel Therapeutics, Inc. stock expensive at its current price?

Whether Candel Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CADL on this page is -9.36. EPS on this page is -1.41. Compare those figures with peers and growth expectations before deciding if the current Candel Therapeutics, Inc. price is justified.

How has the stock price of Candel Therapeutics, Inc. (CADL) performed historically?

Historical performance for Candel Therapeutics, Inc. (CADL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CADL reacted to past earnings and market events.

Should I buy Candel Therapeutics, Inc. (CADL) stock, at this price?

Buying Candel Therapeutics, Inc. (CADL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.